CP 870 Uses, Dosage, Side Effects and more
CP 870 is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
Trade Name | CP 870 |
Generic | Selicrelumab |
Selicrelumab Other Names | CP 870,893, Selicrelumab |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | January 7, 2025 at 1:49 am |